Author:
Magyar Hepato-Pancreatico-Biliaris (HPB) Kutatócsoport 1
Search for other papers by Magyar Hepato-Pancreatico-Biliaris (HPB) Kutatócsoport 1 in
Current site
Google Scholar
PubMed
Close
Magyar Hepato-Pancreatico-Biliaris (HPB) Kutatócsoport 1
Open access
  • 1

    Lesurtel M, Perrier A, Bossuyt PM et al. An independent jury-based consensus conference model for the development of recommendations in medico-surgical practice. Surgery. 2014; 155: 390–397.

  • 2

    Aguayo-Albasini JL, Flores-Pastor B, Soria-Aledo V. [grade system: Classification of quality of evidence and strength of recommendation]. Cir Esp. 2014; 92: 82–88.

  • 3

    Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with child-pugh class a cirrhosis. Am J Med. 1996; 101: 422–434.

  • 4

    Sherman M. Surveillance for hepatocellular carcinoma. Best Pract Res Clin Gastroenterol. 2014; 28: 783–793.

  • 5

    Diaz-Gonzalez A, Forner A. Surveillance for hepatocellular carcinoma. Best Pract Res Clin Gastroenterol. 2016; 30: 1001-1010.

  • 6

    Trevisani F, Santi V, Gramenzi A et al. Surveillance for early diagnosis of hepatocellular carcinoma: Is it effective in intermediate/advanced cirrhosis? Am J Gastroenterol. 2007; 102: 2448-2457; quiz 2458.

  • 7

    Chen CJ, Yang HI, Iloeje UH et al. Hepatitis b virus DNA levels and outcomes in chronic hepatitis b. Hepatology. 2009; 49: S72–84.

  • 8

    Wong VW, Janssen HL. Can we use hcc risk scores to individualize surveillance in chronic hepatitis b infection? J Hepatol. 2015; 63: 722–732.

  • 9

    Yang HI, Yuen MF, Chan HL et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis b (reach-b): Development and validation of a predictive score. Lancet Oncol. 2011; 12: 568–574.

  • 10

    European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. Easl clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018; 69: 182–236.

  • 11

    Kim MN, Kim SU, Kim BK et al. Increased risk of hepatocellular carcinoma in chronic hepatitis b patients with transient elastography-defined subclinical cirrhosis. Hepatology. 2015; 61: 1851–1859.

  • 12

    Lok AS, Seeff LB, Morgan TR et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis c-related advanced liver disease. Gastroenterology. 2009; 136: 138–148.

  • 13

    Masuzaki R, Tateishi R, Yoshida H et al. Risk assessment of hepatocellular carcinoma in chronic hepatitis c patients by transient elastography. J Clin Gastroenterol. 2008; 42: 839–843.

  • 14

    Singh S, Fujii LL, Murad MH et al. Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: A systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013; 11: 1573–1584 e1571–1572; quiz e1588-1579.

  • 15

    Dongiovanni P, Romeo S, Valenti L. Hepatocellular carcinoma in nonalcoholic fatty liver: Role of environmental and genetic factors. World J Gastroenterol. 2014; 20: 12945–12955.

  • 16

    Marengo A, Rosso C, Bugianesi E. Liver cancer: Connections with obesity, fatty liver, and cirrhosis. Annu Rev Med. 2016; 67: 103–117.

  • 17

    Paradis V, Zalinski S, Chelbi E et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: A pathological analysis. Hepatology. 2009; 49: 851–859.

  • 18

    Wong SW, Ting YW, Chan WK. Epidemiology of non-alcoholic fatty liver disease-related hepatocellular carcinoma and its implications. JGH Open. 2018; 2: 235–241.

  • 19

    Bolondi L. Screening for hepatocellular carcinoma in cirrhosis. J Hepatol. 2003; 39: 1076-1084.

  • 20

    Marrero JA, Kulik LM, Sirlin CB et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the american association for the study of liver diseases. Hepatology. 2018; 68: 723-750.

  • 21

    Vogel A, Cervantes A, Chau I et al. Hepatocellular carcinoma: Esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29: iv238-iv255.

  • 22

    Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004; 130: 417–422.

  • 23

    Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018; 391: 1301–1314.

  • 24

    Peng Y, Qi X, Guo X. Child-pugh versus meld score for the assessment of prognosis in liver cirrhosis: A systematic review and meta-analysis of observational studies. Medicine (Baltimore). 2016; 95: e2877.

  • 25

    Foerster F, Mittler J, Darstein F et al. Recipient liver function before liver transplantation influences post-transplantation survival in patients with hcc. Eur J Intern Med. 2018; 55: 57–65.

  • 26

    Kim Y, Kim K, Jang I. Analysis of mortality prognostic factors using model for end-stage liver disease with incorporation of serum-sodium classification for liver cirrhosis complications: A retrospective cohort study. Medicine (Baltimore). 2019; 98: e17862.

  • 27

    Donadon M, Costa G, Cimino M et al. Safe hepatectomy selection criteria for hepatocellular carcinoma patients: A validation of 336 consecutive hepatectomies. The bilche score. World J Surg. 2015; 39: 237–243.

  • 28

    Fagenson AM, Gleeson EM, Pitt HA et al. Albumin-bilirubin score vs model for end-stage liver disease in predicting post-hepatectomy outcomes. J Am Coll Surg. 2020; 230: 637–645.

  • 29

    Pinato DJ, Sharma R, Allara E et al. The albi grade provides objective hepatic reserve estimation across each bclc stage of hepatocellular carcinoma. J Hepatol. 2017; 66: 338–346.

  • 30

    Kokudo T, Hasegawa K, Shirata C et al. Assessment of preoperative liver function for surgical decision making in patients with hepatocellular carcinoma. Liver Cancer. 2019; 8: 447–456.

  • 31

    Schwarz C, Plass I, Fitschek F et al. The value of indocyanine green clearance assessment to predict postoperative liver dysfunction in patients undergoing liver resection. Sci Rep. 2019; 9: 8421.

  • 32

    Nishio T, Taura K, Koyama Y et al. Prediction of posthepatectomy liver failure based on liver stiffness measurement in patients with hepatocellular carcinoma. Surgery. 2016; 159: 399–408.

  • 33

    Procopet B, Fischer P, Horhat A et al. Good performance of liver stiffness measurement in the prediction of postoperative hepatic decompensation in patients with cirrhosis complicated with hepatocellular carcinoma. Med Ultrason. 2018; 20: 272–277.

  • 34

    Berzigotti A, Reig M, Abraldes JG et al. Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: A systematic review and meta-analysis. Hepatology. 2015; 61: 526–536.

  • 35

    Hackl C, Schlitt HJ, Renner P et al. Liver surgery in cirrhosis and portal hypertension. World J Gastroenterol. 2016; 22: 2725–2735.

  • 36

    Boleslawski E, Petrovai G, Truant S et al. Hepatic venous pressure gradient in the assessment of portal hypertension before liver resection in patients with cirrhosis. Br J Surg. 2012; 99: 855–863.

  • 37

    Liu HT, Li ZC, Li C et al. Letter: Elevated hbv DNA predicts poor survival in hepatocellular carcinoma after hepatic resection. Aliment Pharmacol Ther. 2021; 53: 201–202.

  • 38

    Shimoda M, Tago K, Kato M et al. Prognostic factors after curative resection for single-lesion hepatocellular carcinoma in patients with normal liver function: A historical cohort study. Dig Surg. 2017; 34: 281–288.

  • 39

    Yang T, Lu JH, Zhai J et al. High viral load is associated with poor overall and recurrence-free survival of hepatitis b virus-related hepatocellular carcinoma after curative resection: A prospective cohort study. Eur J Surg Oncol. 2012; 38: 683–691.

  • 40

    Singal AG, Lim JK, Kanwal F. Aga clinical practice update on interaction between oral direct-acting antivirals for chronic hepatitis c infection and hepatocellular carcinoma: Expert review. Gastroenterology. 2019; 156: 2149–2157.

  • 41

    Vibert E, Schwartz M, Olthoff KM. Advances in resection and transplantation for hepatocellular carcinoma. J Hepatol. 2020; 72: 262–276.

  • 42

    Manthravadi S, Paleti S, Pandya P. Impact of sustained viral response postcurative therapy of hepatitis c-related hepatocellular carcinoma: A systematic review and meta-analysis. Int J Cancer. 2017; 140: 1042–1049.

  • 43

    Beste LA, Green PK, Berry K et al. Effectiveness of hepatitis c antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma. J Hepatol. 2017; 67: 32–39.

  • 44

    Prenner SB, VanWagner LB, Flamm SL et al. Hepatocellular carcinoma decreases the chance of successful hepatitis c virus therapy with direct-acting antivirals. J Hepatol. 2017; 66: 1173–1181.

  • 45

    Sohn W, Paik YH, Kim JM et al. Hbv DNA and hbsag levels as risk predictors of early and late recurrence after curative resection of hbv-related hepatocellular carcinoma. Ann Surg Oncol. 2014; 21: 2429-2435.

  • 46

    Elsayes KM, Hooker JC, Agrons MM et al. 2017 version of li-rads for ct and mr imaging: An update. Radiographics. 2017; 37: 1994-2017.

  • 47

    Lee YJ, Lee JM, Lee JS et al. Hepatocellular carcinoma: Diagnostic performance of multidetector ct and mr imaging-a systematic review and meta-analysis. Radiology. 2015; 275: 97–109.

  • 48

    Trinchet JC, Chaffaut C, Bourcier V et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: A randomized trial comparing 3- and 6-month periodicities. Hepatology. 2011; 54: 1987-1997.

  • 49

    Chotipanich C, Kunawudhi A, Promteangtrong C et al. Diagnosis of hepatocellular carcinoma using c11 choline pet/ct: Comparison with f18 fdg, contrastenhanced mri and mdct. Asian Pac J Cancer Prev. 2016; 17: 3569–3573.

  • 50

    Forner A, Vilana R, Ayuso C et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology. 2008; 47: 97–104.

  • 51

    Mullhaupt B, Durand F, Roskams T et al. Is tumor biopsy necessary? Liver Transpl. 2011; 17 Suppl 2: S14–25.

  • 52

    Sparchez Z, Mocan T. Contemporary role of liver biopsy in hepatocellular carcinoma. World J Hepatol. 2018; 10: 452–461.

  • 53

    Zhang L, Cai Z, Rodriguez J et al. Fine needle biopsy of malignant tumors of the liver: A retrospective study of 624 cases from a single institution experience. Diagn Pathol. 2020; 15: 43.

  • 54

    Chernyak V, Fowler KJ, Kamaya A et al. Liver imaging reporting and data system (li-rads) version 2018: Imaging of hepatocellular carcinoma in at-risk patients. Radiology. 2018; 289: 816–830.

  • 55

    Cabibbo G, Enea M, Attanasio M et al. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology. 2010; 51: 1274–1283.

  • 56

    de Freitas LBR, Longo L, Santos D et al. Hepatocellular carcinoma staging systems: Hong kong liver cancer vs barcelona clinic liver cancer in a western population. World J Hepatol. 2019; 11: 678–688.

  • 57

    Guglielmi A, Ruzzenente A, Pachera S et al. Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response. Am J Gastroenterol. 2008; 103: 597–604.

  • 58

    Vitale A, Saracino E, Boccagni P et al. Validation of the bclc prognostic system in surgical hepatocellular cancer patients. Transplant Proc. 2009; 41: 1260–1263.

  • 59

    Chang L, Wang Y, Zhang J et al. The best strategy for hcc patients at each bclc stage: A network meta-analysis of observational studies. Oncotarget. 2017; 8: 20418–20427.

  • 60

    Galle PR, Tovoli F, Foerster F et al. The treatment of intermediate stage tumours beyond tace: From surgery to systemic therapy. J Hepatol. 2017; 67: 173–183.

  • 61

    Bai DS, Zhang C, Chen P et al. The prognostic correlation of afp level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. Sci Rep. 2017; 7: 12870.

  • 62

    Bruix J, Cheng AL, Meinhardt G et al. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase iii studies. J Hepatol. 2017; 67: 999–1008.

  • 63

    Chan MY, She WH, Dai WC et al. Prognostic value of preoperative alpha-fetoprotein (afp) level in patients receiving curative hepatectomy- an analysis of 1,182 patients in hong kong. Transl Gastroenterol Hepatol. 2019; 4: 52.

  • 64

    Hameed B, Mehta N, Sapisochin G et al. Alpha-fetoprotein level > 1000 ng/ml as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the milan criteria. Liver Transpl. 2014; 20: 945–951.

  • 65

    Park H, Park JY. Clinical significance of afp and pivka-ii responses for monitoring treatment outcomes and predicting prognosis in patients with hepatocellular carcinoma. Biomed Res Int. 2013; 2013: 310427.

  • 66

    Xing H, Yan C, Cheng L et al. Clinical application of protein induced by vitamin k antagonist-ii as a biomarker in hepatocellular carcinoma. Tumour Biol. 2016.

  • 67

    Zhang D, Liu Z, Yin X et al. Prognostic value of pivka-ii in hepatocellular carcinoma patients receiving curative ablation: A systematic review and meta-analysis. Int J Biol Markers. 2018; 33: 266–274.

  • 68

    Nagtegaal ID, Odze RD, Klimstra D et al. The 2019 who classification of tumours of the digestive system. Histopathology. 2020; 76: 182–188.

  • 69

    Chang PE, Ong WC, Lui HF et al. Is the prognosis of young patients with hepatocellular carcinoma poorer than the prognosis of older patients? A comparative analysis of clinical characteristics, prognostic features, and survival outcome. J Gastroenterol. 2008; 43: 881–888.

  • 70

    Durand F, Levitsky J, Cauchy F et al. Age and liver transplantation. J Hepatol. 2019; 70: 745–758.

  • 71

    Kozyreva ON, Chi D, Clark JW et al. A multicenter retrospective study on clinical characteristics, treatment patterns, and outcome in elderly patients with hepatocellular carcinoma. Oncologist. 2011; 16: 310–318.

  • 72

    Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: A systematic review of 72 studies. Liver Int. 2009; 29: 502–510.

  • 73

    Wu G, Wu J, Wang B et al. Importance of tumor size at diagnosis as a prognostic factor for hepatocellular carcinoma survival: A population-based study. Cancer Manag Res. 2018; 10: 4401–4410.

  • 74

    Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016; 150: 835–853.

  • 75

    European Association For The Study Of The L, European Organisation For R, Treatment Of C. Easl-eortc clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol. 2012; 56: 908–943.

  • 76

    Heimbach JK, Kulik LM, Finn RS et al. Aasld guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018; 67: 358–380.

  • 77

    Kokudo N, Hasegawa K, Akahane M et al. Evidence-based clinical practice guidelines for hepatocellular carcinoma: The japan society of hepatology 2013 update (3rd jsh-hcc guidelines). Hepatol Res. 2015; 45.

  • 78

    Korean Liver Cancer A, National Cancer C. 2018 korean liver cancer association-national cancer center korea practice guidelines for the management of hepatocellular carcinoma. Gut Liver. 2019; 13: 227–299.

  • 79

    Omata M, Cheng AL, Kokudo N et al. Asia-pacific clinical practice guidelines on the management of hepatocellular carcinoma: A 2017 update. Hepatol Int. 2017; 11: 317–370.

  • 80

    Yau T, Tang VY, Yao TJ et al. Development of hong kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology. 2014; 146: 1691-1700 e1693.

  • 81

    Zhou J, Sun HC, Wang Z et al. Guidelines for diagnosis and treatment of primary liver cancer in china (2017 edition). Liver Cancer. 2018; 7: 235–260.

  • 82

    Chen XP, Qiu FZ, Lau WY et al. Mesohepatectomy for hepatocellular carcinoma: A study of 256 patients. Int J Colorectal Dis. 2008; 23: 543–546.

  • 83

    de’Angelis N, Pascal G, Salloum C et al. Central hepatectomy versus extended hepatectomy for malignant tumors: A propensity score analysis of postoperative complications. World J Surg. 2016; 40: 2745–2757.

  • 84

    Hu RH, Lee PH, Chang YC et al. Treatment of centrally located hepatocellular carcinoma with central hepatectomy. Surgery. 2003; 133: 251–256.

  • 85

    Jacobs M, McDonough J, ReMine SG. Resection of central hepatic malignant lesions. Am Surg. 2003; 69: 186-189; discussion 189–190.

  • 86

    Mehrabi A, Mood ZA, Roshanaei N et al. Mesohepatectomy as an option for the treatment of central liver tumors. J Am Coll Surg. 2008; 207: 499–509.

  • 87

    Melendez J, Ferri E, Zwillman M et al. Extended hepatic resection: A 6-year retrospective study of risk factors for perioperative mortality. J Am Coll Surg. 2001; 192: 47–53.

  • 88

    Costentin CE, Decaens T, Laurent A et al. Sorafenib vs surgical resection for hepatocellular carcinoma with macrovascular invasion: A propensity score analysis. Liver Int. 2017; 37: 1869–1876.

  • 89

    Kokudo T, Hasegawa K, Matsuyama Y et al. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol. 2016; 65: 938–943.

  • 90

    Kokudo T, Hasegawa K, Yamamoto S et al. Surgical treatment of hepatocellular carcinoma associated with hepatic vein tumor thrombosis. J Hepatol. 2014; 61: 583–588.

  • 91

    Minagawa M, Makuuchi M, Takayama T et al. Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus. Ann Surg. 2001; 233: 379–384.

  • 92

    Pawlik TM, Poon RT, Abdalla EK et al. Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: Results of a multicenter study. Surgery. 2005; 137: 403–410.

  • 93

    Zhong JH, Rodriguez AC, Ke Y et al. Hepatic resection as a safe and effective treatment for hepatocellular carcinoma involving a single large tumor, multiple tumors, or macrovascular invasion. Medicine (Baltimore). 2015; 94: e396.

  • 94

    Johnson PJ, Berhane S, Kagebayashi C et al. Assessment of liver function in patients with hepatocellular carcinoma: A new evidence-based approach-the albi grade. J Clin Oncol. 2015; 33: 550–558.

  • 95

    Wang YY, Zhong JH, Su ZY et al. Albumin-bilirubin versus child-pugh score as a predictor of outcome after liver resection for hepatocellular carcinoma. Br J Surg. 2016; 103: 725–734.

  • 96

    Cucchetti A, Ercolani G, Vivarelli M et al. Is portal hypertension a contraindication to hepatic resection? Ann Surg. 2009; 250: 922–928.

  • 97

    Kokudo T, Hasegawa K, Amikura K et al. Assessment of preoperative liver function in patients with hepatocellular carcinoma – the albumin-indocyanine green evaluation (alice) grade. PLoS One. 2016; 11: e0159530.

  • 98

    D’Onofrio M, De Robertis R, Demozzi E et al. Liver volumetry: Is imaging reliable? Personal experience and review of the literature. World J Radiol. 2014; 6: 62–71.

  • 99

    Rassam F, Olthof PB, Bennink RJ et al. Current modalities for the assessment of future remnant liver function. Visc Med. 2017; 33: 442–448.

  • 100

    Vauthey JN, Chaoui A, Do KA et al. Standardized measurement of the future liver remnant prior to extended liver resection: Methodology and clinical associations. Surgery. 2000; 127: 512–519.

  • 101

    Adams RB, Aloia TA, Loyer E et al. Selection for hepatic resection of colorectal liver metastases: Expert consensus statement. HPB (Oxford). 2013; 15: 91–103.

  • 102

    Kishi Y, Abdalla EK, Chun YS et al. Three hundred and one consecutive extended right hepatectomies: Evaluation of outcome based on systematic liver volumetry. Ann Surg. 2009; 250: 540–548.

  • 103

    Shindoh J, Tzeng CW, Aloia TA et al. Optimal future liver remnant in patients treated with extensive preoperative chemotherapy for colorectal liver metastases. Ann Surg Oncol. 2013; 20: 2493–2500.

  • 104

    Chapelle T, Op De Beeck B, Huyghe I et al. Future remnant liver function estimated by combining liver volumetry on magnetic resonance imaging with total liver function on (99m)tc-mebrofenin hepatobiliary scintigraphy: Can this tool predict post-hepatectomy liver failure? HPB (Oxford). 2016; 18: 494–503.

  • 105

    de Graaf W, van Lienden KP, Dinant S et al. Assessment of future remnant liver function using hepatobiliary scintigraphy in patients undergoing major liver resection. J Gastrointest Surg. 2010; 14: 369–378.

  • 106

    Schroeder RA, Marroquin CE, Bute BP et al. Predictive indices of morbidity and mortality after liver resection. Ann Surg. 2006; 243: 373–379.

  • 107

    Aoki T, Kubota K. Preoperative portal vein embolization for hepatocellular carcinoma: Consensus and controversy. World J Hepatol. 2016; 8: 439–445.

  • 108

    Giglio MC, Giakoustidis A, Draz A et al. Oncological outcomes of major liver resection following portal vein embolization: A systematic review and meta-analysis. Ann Surg Oncol. 2016; 23: 3709–3717.

  • 109

    Glantzounis GK, Tokidis E, Basourakos SP et al. The role of portal vein embolization in the surgical management of primary hepatobiliary cancers. A systematic review. Eur J Surg Oncol. 2017; 43: 32–41.

  • 110

    Szijarto A, Fulop A. [surgical treatment of primary liver malignancies]. Magy Onkol. 2018; 62: 14–25.

  • 111

    van Lienden KP, van den Esschert JW, de Graaf W et al. Portal vein embolization before liver resection: A systematic review. Cardiovasc Intervent Radiol. 2013; 36: 25–34.

  • 112

    Isfordink CJ, Samim M, Braat M et al. Portal vein ligation versus portal vein embolization for induction of hypertrophy of the future liver remnant: A systematic review and meta-analysis. Surg Oncol. 2017; 26: 257–267.

  • 113

    Ribero D, Abdalla EK, Madoff DC et al. Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome. Br J Surg. 2007; 94: 1386–1394.

  • 114

    Abulkhir A, Limongelli P, Healey AJ et al. Preoperative portal vein embolization for major liver resection: A meta-analysis. Ann Surg. 2008; 247: 49–57.

  • 115

    Aoki T, Imamura H, Hasegawa K et al. Sequential preoperative arterial and portal venous embolizations in patients with hepatocellular carcinoma. Arch Surg. 2004; 139: 766–774.

  • 116

    Ronot M, Cauchy F, Gregoli B et al. Sequential transarterial chemoembolization and portal vein embolization before resection is a valid oncological strategy for unilobar hepatocellular carcinoma regardless of the tumor burden. HPB (Oxford). 2016; 18: 684–690.

  • 117

    Brown KT, Do RK, Gonen M et al. Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone. J Clin Oncol. 2016; 34: 2046–2053.

  • 118

    Meyer T, Kirkwood A, Roughton M et al. A randomised phase ii/iii trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. Br J Cancer. 2013; 108: 1252–1259.

  • 119

    Xie ZB, Ma L, Wang XB et al. Transarterial embolization with or without chemotherapy for advanced hepatocellular carcinoma: A systematic review. Tumour Biol. 2014; 35: 8451–8459.

  • 120

    Chan AC, Poon RT, Chan C et al. Safety of alpps procedure by the anterior approach for hepatocellular carcinoma. Ann Surg. 2016; 263: e14–16.

  • 121

    Chan ACY, Chok K, Dai JWC et al. Impact of split completeness on future liver remnant hypertrophy in associating liver partition and portal vein ligation for staged hepatectomy (alpps) in hepatocellular carcinoma: Complete-alpps versus partial-alpps. Surgery. 2017; 161: 357–364.

  • 122

    Lopez-Lopez V, Robles-Campos R, Brusadin R et al. Alpps for hepatocarcinoma under cirrhosis: A feasible alternative to portal vein embolization. Ann Transl Med. 2019; 7: 691.

  • 123

    Serenari M, Zanello M, Schadde E et al. Importance of primary indication and liver function between stages: Results of a multicenter italian audit of alpps 2012-2014. HPB (Oxford). 2016; 18: 419–427.

  • 124

    Abu Hilal M, Aldrighetti L, Dagher I et al. The southampton consensus guidelines for laparoscopic liver surgery: From indication to implementation. Ann Surg. 2018; 268: 11–18.

  • 125

    Ciria R, Cherqui D, Geller DA et al. Comparative short-term benefits of laparoscopic liver resection: 9000 cases and climbing. Ann Surg. 2016; 263: 761–777.

  • 126

    Scuderi V, Barkhatov L, Montalti R et al. Outcome after laparoscopic and open resections of posterosuperior segments of the liver. Br J Surg. 2017; 104: 751–759.

  • 127

    El-Gendi A, El-Shafei M, El-Gendi S et al. Laparoscopic versus open hepatic resection for solitary hepatocellular carcinoma less than 5 cm in cirrhotic patients: A randomized controlled study. J Laparoendosc Adv Surg Tech A. 2018; 28: 302–310.

  • 128

    Li SQ, Huang T, Shen SL et al. Anatomical versus non-anatomical liver resection for hepatocellular carcinoma exceeding milan criteria. Br J Surg. 2017; 104: 118–127.

  • 129

    Marubashi S, Gotoh K, Akita H et al. Anatomical versus non-anatomical resection for hepatocellular carcinoma. Br J Surg. 2015; 102: 776–784.

  • 130

    Shindoh J, Makuuchi M, Matsuyama Y et al. Complete removal of the tumor-bearing portal territory decreases local tumor recurrence and improves disease-specific survival of patients with hepatocellular carcinoma. J Hepatol. 2016; 64: 594–600.

  • 131

    Yamamoto T, Yagi S, Uryuhara K et al. Clinical factors that affect the outcomes after anatomical versus non-anatomical resection for hepatocellular carcinoma. Surg Today. 2017; 47: 193-201.

  • 132

    Zhao J, Li W, Mao J. Early versus late recurrence of centrally located hepatocellular carcinoma after mesohepatectomy: A cohort study based on the strobe guidelines. Medicine (Baltimore). 2019; 98: e15540.

  • 133

    Aoki T, Kubota K, Hasegawa K et al. Significance of the surgical hepatic resection margin in patients with a single hepatocellular carcinoma. Br J Surg. 2020; 107: 113-120.

  • 134

    Donadon M, Terrone A, Procopio F et al. Is r1 vascular hepatectomy for hepatocellular carcinoma oncologically adequate? Analysis of 327 consecutive patients. Surgery. 2019; 165: 897-904.

  • 135

    Tsilimigras DI, Sahara K, Moris D et al. Effect of surgical margin width on patterns of recurrence among patients undergoing r0 hepatectomy for t1 hepatocellular carcinoma: An international multi-institutional analysis. J Gastrointest Surg. 2020; 24: 1552–1560.

  • 136

    Yang P, Si A, Yang J et al. A wide-margin liver resection improves long-term outcomes for patients with hbv-related hepatocellular carcinoma with microvascular invasion. Surgery. 2019; 165: 721–730.

  • 137

    Zhong FP, Zhang YJ, Liu Y et al. Prognostic impact of surgical margin in patients with hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore). 2017; 96: e8043.

  • 138

    Cerrito L, Annicchiarico BE, Iezzi R et al. Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers. World J Gastroenterol. 2019; 25: 4360–4382.

  • 139

    Chen XP, Qiu FZ, Wu ZD et al. Effects of location and extension of portal vein tumor thrombus on long-term outcomes of surgical treatment for hepatocellular carcinoma. Ann Surg Oncol. 2006; 13: 940-946.

  • 140

    Kokudo T, Hasegawa K, Matsuyama Y et al. Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: A japanese nationwide survey. Hepatology. 2017; 66: 510-517.

  • 141

    Peng SY, Wang XA, Huang CY et al. Better surgical treatment method for hepatocellular carcinoma with portal vein tumor thrombus. World J Gastroenterol. 2018; 24: 4527–4535.

  • 142

    Pesi B, Ferrero A, Grazi GL et al. Liver resection with thrombectomy as a treatment of hepatocellular carcinoma with major vascular invasion: Results from a retrospective multicentric study. Am J Surg. 2015; 210: 35–44.

  • 143

    Pesi B, Giudici F, Moraldi L et al. Hepatocellular carcinoma on cirrhosis complicated with tumoral thrombi extended to the right atrium: Results in three cases treated with major hepatectomy and thrombectomy under hypothermic cardiocirculatory arrest and literature review. World J Surg Oncol. 2016; 14: 83.

  • 144

    Yoshidome H, Takeuchi D, Kimura F et al. Treatment strategy for hepatocellular carcinoma with major portal vein or inferior vena cava invasion: A single institution experience. J Am Coll Surg. 2011; 212: 796–803.

  • 145

    Zhang XP, Wang K, Li N et al. Survival benefit of hepatic resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: A systematic review and meta-analysis. BMC Cancer. 2017; 17: 902.

  • 146

    Zhang Y, Wu Z, Wang K et al. Long-term survival after anterior approach right hepatectomy combined with inferior vena cava thrombectomy using trans-diaphragmatic intrapericardial inferior vena cava occlusion: A case report and review of the literature. BMC Surg. 2019; 19: 122.

  • 147

    Mise Y, Hasegawa K, Shindoh J et al. The feasibility of third or more repeat hepatectomy for recurrent hepatocellular carcinoma. Ann Surg. 2015; 262: 347–357.

  • 148

    Yang PC, Ho CM, Hu RH et al. Prophylactic liver transplantation for high-risk recurrent hepatocellular carcinoma. World J Hepatol. 2016; 8: 1309–1317.

  • 149

    Ahn SH, Kim SH, Choi GH et al. The optimal follow-up period in patients with above 5-year disease-free survival after curative liver resection for hepatocellular carcinoma. J Korean Surg Soc. 2013; 85: 269–274.

  • 150

    Dimitroulis D, Damaskos C, Valsami S et al. From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world. World J Gastroenterol. 2017; 23: 5282–5294.

  • 151

    Hatzaras I, Bischof DA, Fahy B et al. Treatment options and surveillance strategies after therapy for hepatocellular carcinoma. Ann Surg Oncol. 2014; 21: 758–766.

  • 152

    He W, Zheng Y, Zou R et al. Long- versus short-interval follow-up after resection of hepatocellular carcinoma: A retrospective cohort study. Cancer Commun (Lond). 2018; 38: 26.

  • 153

    Kishi Y, Shimada K, Nara S et al. Role of hepatectomy for recurrent or initially unresectable hepatocellular carcinoma. World J Hepatol. 2014; 6: 836–843.

  • 154

    Lacaze L, Scotte M. Surgical treatment of intra hepatic recurrence of hepatocellular carcinoma. World J Hepatol. 2015; 7: 1755–1760.

  • 155

    Xia Y, Li J, Liu G et al. Long-term effects of repeat hepatectomy vs percutaneous radiofrequency ablation among patients with recurrent hepatocellular carcinoma: A randomized clinical trial. JAMA Oncol. 2020; 6: 255–263.

  • 156

    Mazzaferro V, Bhoori S, Sposito C et al. Milan criteria in liver transplantation for hepatocellular carcinoma: An evidence-based analysis of 15 years of experience. Liver Transpl. 2011; 17 Suppl 2: S44–57.

  • 157

    Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996; 334: 693–699.

  • 158

    Yao FY, Ferrell L, Bass NM et al. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001; 33: 1394–1403.

  • 159

    Yao FY, Xiao L, Bass NM et al. Liver transplantation for hepatocellular carcinoma: Validation of the ucsf-expanded criteria based on preoperative imaging. Am J Transplant. 2007; 7: 2587–2596.

  • 160

    Andreou A, Bahra M, Schmelzle M et al. Predictive factors for extrahepatic recurrence of hepatocellular carcinoma following liver transplantation. Clin Transplant. 2016; 30: 819–827.

  • 161

    Clavien PA, Lesurtel M, Bossuyt PM et al. Recommendations for liver transplantation for hepatocellular carcinoma: An international consensus conference report. Lancet Oncol. 2012; 13: e11–22.

  • 162

    de Haas RJ, Lim C, Bhangui P et al. Curative salvage liver transplantation in patients with cirrhosis and hepatocellular carcinoma: An intention-to-treat analysis. Hepatology. 2018; 67: 204–215.

  • 163

    Otsuka Y, Duffy JP, Saab S et al. Postresection hepatic failure: Successful treatment with liver transplantation. Liver Transpl. 2007; 13: 672–679.

  • 164

    European Association for the Study of the Liver. Electronic address eee. Easl clinical practice guidelines: Liver transplantation. J Hepatol. 2016; 64: 433–485.

  • 165

    Llovet JM, Mas X, Aponte JJ et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut. 2002; 50: 123–128.

  • 166

    Yamaoka Y, Washida M, Honda K et al. Liver transplantation using a right lobe graft from a living related donor. Transplantation. 1994; 57: 1127–1130.

  • 167

    Neuberger JM, Bechstein WO, Kuypers DR et al. Practical recommendations for long-term management of modifiable risks in kidney and liver transplant recipients: A guidance report and clinical checklist by the consensus on managing modifiable risk in transplantation (commit) group. Transplantation. 2017; 101: S1–S56.

  • 168

    Cho YK, Kim JK, Kim MY et al. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology. 2009; 49: 453–459.

  • 169

    Germani G, Pleguezuelo M, Gurusamy K et al. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: A meta-analysis. J Hepatol. 2010; 52: 380–388.

  • 170

    Izzo F, Granata V, Grassi R et al. Radiofrequency ablation and microwave ablation in liver tumors: An update. Oncologist. 2019; 24: e990–e1005.

  • 171

    Shiina S, Sato K, Tateishi R et al. Percutaneous ablation for hepatocellular carcinoma: Comparison of various ablation techniques and surgery. Can J Gastroenterol Hepatol. 2018; 2018: 4756147.

  • 172

    Cho YK, Kim JK, Kim WT et al. Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: A markov model analysis. Hepatology. 2010; 51: 1284–1290.

  • 173

    Cucchetti A, Piscaglia F, Cescon M et al. Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. J Hepatol. 2013; 59: 300–307.

  • 174

    Bhagavatula SK, Chick JF, Chauhan NR et al. Artificial ascites and pneumoperitoneum to facilitate thermal ablation of liver tumors: A pictorial essay. Abdom Radiol (NY). 2017; 42: 620–630.

  • 175

    Buy X, Tok CH, Szwarc D et al. Thermal protection during percutaneous thermal ablation procedures: Interest of carbon dioxide dissection and temperature monitoring. Cardiovasc Intervent Radiol. 2009; 32: 529–534.

  • 176

    Ohnishi T, Yasuda I, Nishigaki Y et al. Intraductal chilled saline perfusion to prevent bile duct injury during percutaneous radio frequency ablation for hepatocellular carcinoma. J Gastroenterol Hepatol. 2008; 23: e410–415.

  • 177

    Raman SS, Aziz D, Chang X et al. Minimizing diaphragmatic injury during radiofrequency ablation: Efficacy of intraabdominal carbon dioxide insufflation. AJR Am J Roentgenol. 2004; 183: 197–200.

  • 178

    Song I, Rhim H, Lim HK et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma abutting the diaphragm and gastrointestinal tracts with the use of artificial ascites: Safety and technical efficacy in 143 patients. Eur Radiol. 2009; 19: 2630–2640.

  • 179

    Nault JC, Nkontchou G, Nahon P et al. Percutaneous treatment of localized infiltrative hepatocellular carcinoma developing on cirrhosis. Ann Surg Oncol. 2016; 23: 1906–1915.

  • 180

    Sarpel U, Ayo D, Lobach I et al. Inverse relationship between cirrhosis and massive tumours in hepatocellular carcinoma. HPB (Oxford). 2012; 14: 741–745.

  • 181

    Ziol M, Pote N, Amaddeo G et al. Macrotrabecular-massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance. Hepatology. 2018; 68: 103–112.

  • 182

    Laimer G, Schullian P, Jaschke N et al. Minimal ablative margin (mam) assessment with image fusion: An independent predictor for local tumor progression in hepatocellular carcinoma after stereotactic radiofrequency ablation. Eur Radiol. 2020; 30: 2463–2472.

  • 183

    Widmann G, Schullian P, Haidu M et al. Stereotactic radiofrequency ablation (srfa) of liver lesions: Technique effectiveness, safety, and interoperator performance. Cardiovasc Intervent Radiol. 2012; 35: 570–580.

  • 184

    Han K, Kim JH. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system. World J Gastroenterol. 2015; 21: 10327–10335.

  • 185

    Vogel A, Cervantes A, Chau I et al. Hepatocellular carcinoma: Esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019; 30: 871–873.

  • 186

    Burrel M, Reig M, Forner A et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (tace) using drug eluting beads. Implications for clinical practice and trial design. J Hepatol. 2012; 56: 1330–1335.

  • 187

    Malagari K, Pomoni M, Moschouris H et al. Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: Five-year survival analysis. Cardiovasc Intervent Radiol. 2012; 35: 1119–1128.

  • 188

    Takayasu K, Arii S, Kudo M et al. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by japanese guidelines. J Hepatol. 2012; 56: 886–892.

  • 189

    Chow PKH, Gandhi M, Tan SB et al. Sirvenib: Selective internal radiation therapy versus sorafenib in asia-pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018; 36: 1913–1921.

  • 190

    Vilgrain V, Pereira H, Assenat E et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (sarah): An open-label randomised controlled phase 3 trial. Lancet Oncol. 2017; 18: 1624-1636.

  • 191

    Lammer J, Malagari K, Vogl T et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: Results of the precision v study. Cardiovasc Intervent Radiol. 2010; 33: 41–52.

  • 192

    Lo CM, Ngan H, Tso WK et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002; 35: 1164–1171.

  • 193

    Silva JP, Berger NG, Tsai S et al. Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: A systematic review and meta-analysis. HPB (Oxford). 2017; 19: 659–666.

  • 194

    Parikh ND, Waljee AK, Singal AG. Downstaging hepatocellular carcinoma: A systematic review and pooled analysis. Liver Transpl. 2015; 21: 1142–1152.

  • 195

    Hucke F, Sieghart W, Pinter M et al. The art-strategy: Sequential assessment of the art score predicts outcome of patients with hepatocellular carcinoma re-treated with tace. J Hepatol. 2014; 60: 118–126.

  • 196

    Kudo M, Han G, Finn RS et al. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase iii trial. Hepatology. 2014; 60: 1697–1707.

  • 197

    Lencioni R, Llovet JM, Han G et al. Sorafenib or placebo plus tace with doxorubicin-eluting beads for intermediate stage hcc: The space trial. J Hepatol. 2016; 64: 1090–1098.

  • 198

    Peng ZW, Zhang YJ, Chen MS et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: A prospective randomized trial. J Clin Oncol. 2013; 31: 426–432.

  • 199

    Wang X, Hu Y, Ren M et al. Efficacy and safety of radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinomas compared with radiofrequency ablation alone: A time-to-event meta-analysis. Korean J Radiol. 2016; 17: 93–102.

  • 200

    Iezzi R, Pompili M, La Torre MF et al. Radiofrequency ablation plus drug-eluting beads transcatheter arterial chemoembolization for the treatment of single large hepatocellular carcinoma. Dig Liver Dis. 2015; 47: 242–248.

  • 201

    Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359: 378–390.

  • 202

    Akateh C, Black SM, Conteh L et al. Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. World J Gastroenterol. 2019; 25: 3704–3721.

  • 203

    Brown ZJ, Greten TF, Heinrich B. Adjuvant treatment of hepatocellular carcinoma: Prospect of immunotherapy. Hepatology. 2019; 70: 1437–1442.

  • 204

    Bruix J, Takayama T, Mazzaferro V et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (storm): A phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015; 16: 1344–1354.

  • 205

    Geissler EK, Schnitzbauer AA, Zulke C et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: A randomized, multicenter, open-label phase 3 trial. Transplantation. 2016; 100: 116–125.

  • 206

    Bruix J, Cheng AL, Meinhardt G et al. Corrigendum to „prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase iii studies” [J Hepatol 67 (2017) 999–1008]. J Hepatol. 2018; 69: 990–991.

  • 207

    Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the asia-pacific region with advanced hepatocellular carcinoma: A phase iii randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10: 25–34.

  • 208

    Finn RS, Qin S, Ikeda M et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020; 382: 1894–1905.

  • 209

    Kudo M, Finn RS, Qin S et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet. 2018; 391: 1163–1173.

  • 210

    Salem R, Li D, Sommer N et al. Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the imbrave150 trial. Cancer Med. 2021.

  • 211

    Abou-Alfa GK, Meyer T, Cheng AL et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018; 379: 54–63.

  • 212

    Bruix J, Qin S, Merle P et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (resorce): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017; 389: 56–66.

  • 213

    Gordan JD, Kennedy EB, Abou-Alfa GK et al. Systemic therapy for advanced hepatocellular carcinoma: Asco guideline. J Clin Oncol. 2020; 38: 4317–4345.

  • 214

    Llovet JM, Villanueva A, Marrero JA et al. Trial design and endpoints in hepatocellular carcinoma: Aasld consensus conference. Hepatology. 2021; 73 Suppl 1: 158–191.

  • 215

    Zhu AX, Kang YK, Yen CJ et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (reach-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019; 20: 282–296.

  • 216

    Yau T, Kang YK, Kim TY et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: The checkmate 040 randomized clinical trial. JAMA Oncol. 2020; 6: e204564.

  • 217

    Zhu AX, Finn RS, Edeline J et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (keynote-224): A non-randomised, open-label phase 2 trial. Lancet Oncol. 2018; 19: 940–952.

  • 218

    Gish RG, Porta C, Lazar L et al. Phase iii randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol. 2007; 25: 3069-3075.

  • 219

    Qin S, Bai Y, Lim HY et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from asia. J Clin Oncol. 2013; 31: 3501–3508.

  • 220

    Yeo W, Mok TS, Zee B et al. A randomized phase iii study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (piaf) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst. 2005; 97: 1532–1538.

  • 221

    Eso Y, Shimizu T, Takeda H et al. Microsatellite instability and immune checkpoint inhibitors: Toward precision medicine against gastrointestinal and hepatobiliary cancers. J Gastroenterol. 2020; 55: 15–26.

  • 222

    Zucman-Rossi J, Villanueva A, Nault JC et al. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology. 2015; 149: 1226–1239 e1224.

  • 223

    Lencioni R, Llovet JM. Modified recist (mrecist) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010; 30: 52–60.

  • 224

    Marrero JA, Feng Z, Wang Y et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009; 137: 110–118.

  • 225

    Bartsch F, Heinrich S, Roth W et al. [lymphadenectomy in oncological visceral surgery-part 1: Hepatobiliary tumors and pancreatic cancer]. Chirurg. 2019; 90: 423–438.

  • 226

    Berger Y, Spivack JH, Heskel M et al. Extrahepatic metastasectomy for hepatocellular carcinoma: Predictors of long-term survival. J Surg Oncol. 2016; 114: 469-474.

  • 227

    Ji ZH, An SL, Li XB et al. Long-term progression-free survival of hepatocellular carcinoma with synchronous diffuse peritoneal metastasis treated by crs+hipec: A case report and literature review. Medicine (Baltimore). 2019; 98: e14628.

  • 228

    Settmacher U, Schule S. [surgical treatment of peritoneal malignancies]. Chirurg. 2018; 89: 661–662.

  • 229

    Jang WI, Bae SH, Kim MS et al. A phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: Safety and efficacy. Cancer. 2020; 126: 363–372.

  • 230

    Kang J, Nie Q, Du R et al. Stereotactic body radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis. Mol Clin Oncol. 2014; 2: 43–50.

  • 231

    Rim CH, Kim HJ, Seong J. Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. Radiother Oncol. 2019; 131: 135–144.

  • 232

    Sapisochin G, Barry A, Doherty M et al. Stereotactic body radiotherapy vs. Tace or rfa as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J Hepatol. 2017; 67: 92–99.

  • 233

    Shui Y, Yu W, Ren X et al. Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis. Radiat Oncol. 2018; 13: 188.

  • 234

    Xi M, Zhang L, Zhao L et al. Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombosis. PLoS One. 2013; 8: e63864.

  • 235

    Bush DA, Smith JC, Slater JD et al. Randomized clinical trial comparing proton beam radiation therapy with transarterial chemoembolization for hepatocellular carcinoma: Results of an interim analysis. Int J Radiat Oncol Biol Phys. 2016; 95: 477-482.

  • 236

    Hata M, Tokuuye K, Sugahara S et al. Proton beam therapy for hepatocellular carcinoma patients with severe cirrhosis. Strahlenther Onkol. 2006; 182: 713–720.

  • 237

    Mizumoto M, Oshiro Y, Okumura T et al. Proton beam therapy for hepatocellular carcinoma: A review of the university of tsukuba experience. Int J Part Ther. 2016; 2: 570–578.

  • 238

    Sugahara S, Oshiro Y, Nakayama H et al. Proton beam therapy for large hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2010; 76: 460–466.

  • 239

    Yoo GS, Yu JI, Park HC. Proton therapy for hepatocellular carcinoma: Current knowledges and future perspectives. World J Gastroenterol. 2018; 24: 3090–3100.

  • 240

    Casamassima F, Livi L, Masciullo S et al. Stereotactic radiotherapy for adrenal gland metastases: University of florence experience. Int J Radiat Oncol Biol Phys. 2012; 82: 919–923.

  • 241

    He J, Zeng ZC, Tang ZY et al. Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma receiving external beam radiotherapy. Cancer. 2009; 115: 2710–2720.

  • 242

    Jiang W, Zeng ZC, Zhang JY et al. Palliative radiation therapy for pulmonary metastases from hepatocellular carcinoma. Clin Exp Metastasis. 2012; 29: 197–205.

  • 243

    Jung IH, Yoon SM, Kwak J et al. High-dose radiotherapy is associated with better local control of bone metastasis from hepatocellular carcinoma. Oncotarget. 2017; 8: 15182–15192.

  • 244

    Jung J, Yoon SM, Park HC et al. Radiotherapy for adrenal metastasis from hepatocellular carcinoma: A multi-institutional retrospective study (krog 13–05). PLoS One. 2016; 11: e0152642.

  • 245

    Kaizu T, Karasawa K, Tanaka Y et al. Radiotherapy for osseous metastases from hepatocellular carcinoma: A retrospective study of 57 patients. Am J Gastroenterol. 1998; 93: 2167–2171.

  • 246

    Ogino A, Hirai T, Serizawa T et al. Clinical features of brain metastases from hepatocellular carcinoma using gamma knife surgery. Acta Neurochir (Wien). 2018; 160: 997–1003.

  • 247

    Park JW, Chen M, Colombo M et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: The bridge study. Liver Int. 2015; 35: 2155–2166.

  • 248

    Ratanatharathorn V, Powers WE, Moss WT et al. Bone metastasis: Review and critical analysis of random allocation trials of local field treatment. Int J Radiat Oncol Biol Phys. 1999; 44: 1–18.

  • 249

    Seong J, Koom WS, Park HC. Radiotherapy for painful bone metastases from hepatocellular carcinoma. Liver Int. 2005; 25: 261–265.

  • 250

    Sun T, He J, Zhang S et al. Simultaneous multitarget radiotherapy using helical tomotherapy and its combination with sorafenib for pulmonary metastases from hepatocellular carcinoma. Oncotarget. 2016; 7: 48586–48599.

  • 251

    Wang S, Wang A, Lin J et al. Brain metastases from hepatocellular carcinoma: Recent advances and future avenues. Oncotarget. 2017; 8: 25814–25829.

  • 252

    Watanabe J, Nakashima O, Kojiro M. Clinicopathologic study on lymph node metastasis of hepatocellular carcinoma: A retrospective study of 660 consecutive autopsy cases. Jpn J Clin Oncol. 1994; 24: 37–41.

  • 253

    Zeng ZC, Tang ZY, Fan J et al. Consideration of role of radiotherapy for lymph node metastases in patients with hcc: Retrospective analysis for prognostic factors from 125 patients. Int J Radiat Oncol Biol Phys. 2005; 63: 1067–1076.

  • 254

    Zhang H, Chen Y, Hu Y et al. Image-guided intensity-modulated radiotherapy improves short-term survival for abdominal lymph node metastases from hepatocellular carcinoma. Ann Palliat Med. 2019; 8: 717–727.

  • 255

    Zhou LY, Zeng ZC, Fan J et al. Radiotherapy treatment of adrenal gland metastases from hepatocellular carcinoma: Clinical features and prognostic factors. BMC Cancer. 2014; 14: 878.

  • 256

    Honda Y, Kimura T, Aikata H et al. Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma. J Gastroenterol Hepatol. 2013; 28: 530–536.

  • 257

    Jacob R, Turley F, Redden DT et al. Adjuvant stereotactic body radiotherapy following transarterial chemoembolization in patients with non-resectable hepatocellular carcinoma tumours of >/= 3 cm. HPB (Oxford). 2015; 17: 140–149.

  • 258

    Paik EK, Kim MS, Jang WI et al. Benefits of stereotactic ablative radiotherapy combined with incomplete transcatheter arterial chemoembolization in hepatocellular carcinoma. Radiat Oncol. 2016; 11: 22.

  • 259

    Llovet JM, Zucman-Rossi J, Pikarsky E et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016; 2: 16018.

  • 260

    Sasaki Y, Yamada T, Tanaka H et al. Risk of recurrence in a long-term follow-up after surgery in 417 patients with hepatitis b- or hepatitis c-related hepatocellular carcinoma. Ann Surg. 2006; 244: 771–780.

  • 261

    Shan QY, Hu HT, Feng ST et al. Ct-based peritumoral radiomics signatures to predict early recurrence in hepatocellular carcinoma after curative tumor resection or ablation. Cancer Imaging. 2019; 19: 11.

  • 262

    Crocetti L, de Baere T, Lencioni R. Quality improvement guidelines for radiofrequency ablation of liver tumours. Cardiovasc Intervent Radiol. 2010; 33: 11–17.

  • 263

    Lencioni R, Montal R, Torres F et al. Objective response by mrecist as a predictor and potential surrogate end-point of overall survival in advanced hcc. J Hepatol. 2017; 66: 1166–1172.

  • 264

    Dioguardi Burgio M, Ronot M, Fuks D et al. Follow-up imaging after liver transplantation should take into consideration primary hepatocellular carcinoma characteristics. Transplantation. 2015; 99: 1613–1618.

  • 265

    Roberts JP. Tumor surveillance-what can and should be done? Screening for recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl. 2005: S45–46.

  • 266

    Yin W, Ye Q, Wang F et al. Art score and hepatocellular carcinoma: An appraisal of its applicability. Clin Res Hepatol Gastroenterol. 2016; 40: 705–714.

  • Collapse
  • Expand
The author instructions are available in PDF.
Instructions for Authors in Hungarian HERE.
Mendeley citation style is available HERE.

Főszerkesztő - Editor-in-Chief:
 
Zoltán PAPP (professor emeritus, Semmelweis Egyetem, Szülészeti és Nőgyógyászati Klinika, Budapest)

Read the professional career of Zoltán PAPP HERE.

All scientific publications of Zoltán PAPP are collected in the Hungarian Scientific Bibliography.

Főszerkesztő-helyettesek - Assistant Editors-in-Chief: 

  • Erzsébet FEHÉR (professor emeritus, Semmelweis Egyetem, Anatómiai, Szövet- és Fejlődéstani Intézet)
  • Krisztina HAGYMÁSI (egyetemi docens, Semmelweis Egyetem, I. Sebészeti és Intervenciós Gasztroenterológiai Klinika, Budapest)

Főmunkatársak - Senior Editorial Specialists:

  • László KISS (a Debreceni Egyetem habilitált doktora)
  • Gabriella LENGYEL (ny. egyetemi docens, Semmelweis Egyetem, I. Sebészeti és Intervenciós Gasztroenterológiai Klinika, Budapest)
  • Alajos PÁR (professor emeritus, Pécsi Tudományegyetem, I. Belgyógyászati Klinika)

 A Szerkesztőbizottság tagjai – Members of the Editorial Board:

  • Péter ANDRÉKA (főigazgató, Gottsegen György Országos Kardiovaszkuláris Intézet, Nemzeti Szívinfartkus Regiszter, Budapest)
  • Géza ÁCS Jr. (egyetemi tanár Floridában)
  • Csaba BALÁZS (egyetemi tanár, Budai Endokrinközpont, Budapest)
  • Zoltán BENYÓ (egyetemi tanár, Semmelweis Egyetem, Transzlációs Medicina Intézet, Budapest)
  • Dániel BERECZKI (egyetemi tanár, Semmelweis Egyetem, Neurológiai Klinika, Budapest)
  • Anna BLÁZOVICS (professor emeritus, Semmelweis Egyetem, Farmakognóziai Intézet, Budapest)
  • Lajos BOGÁR (egyetemi tanár, Pécsi Tudományegyetem, Klinikai Központ, Aneszteziológiai és Intenzív Terápiás Intézet, Pécs)
  • Katalin DARVAS (professor emeritus, Semmelweis Egyetem, Általános Orvostudományi Kar, Sebészeti, Transzplantációs és Gasztroenterológiai Klinika, továbbá Aneszteziológiai és Intenzív Terápiás Klinika, Budapest)
  • Elek DINYA (professor emeritus, biostatisztikus, Semmelweis Egyetem, Budapest)
  • Attila DOBOZY (professor emeritus, Szegedi Tudományegyetem, Bőrgyógyászati Klinika, Szeged)
  • András FALUS (professor emeritus, Semmelweis Egyetem, Genetikai, Sejt- és Immunbiológiai Intézet, Budapest)
  • Csaba FARSANG (egyetemi tanár, Szent Imre Oktató Kórház, Belgyógyászati Osztály, Budapest)
  • Béla FÜLESDI (egyetemi tanár, Debreceni Egyetem, Aneszteziológiai és Intenzív Terápiás Klinika, Debrecen)
  • István GERA (professor emeritus, Semmelweis Egyetem, Fogorvostudományi Kar, Parodontológiai Klinika, Budapest)
  • Beáta GASZTONYI (egyetemi magántanár, kórházi főorvos, Zala Megyei Kórház, Belgyógyászat, Zalaegerszeg)
  • István GERGELY (egyetemi docens, Marosvásárhelyi Orvosi és Gyógyszerészeti Egyetem, Románia)
  • Judit GERVAIN (osztályvezető főorvos, Fejér Megyei Szent György Kórház, Belgyógyászat, Székesfehérvár)
  • Béla GÖMÖR (professor emeritus, Budai Irgalmasrendi Kórház, Reumatológiai Osztály, Budapest)
  • János HANKISS (professor emeritus, Markusovszky Lajos Oktató Kórház, Belgyógyászati Osztály, Szombathely)
  • Andor HIRSCHBERG (c. egyetemi tanár, Észak-budai Szent János Centrumkórház, Fül-, Orr-, Gége-, Fej-Nyak és Szájsebészeti Osztály, Budapest)
  • Örs Péter HORVÁTH (professor emeritus, Pécsi Tudományegyetem, Sebészeti Klinika, Pécs)
  • Béla HUNYADY (egyetemi tanár, Somogy Megyei Kaposi Mór Kórház, Belgyógyászat, Kaposvár)
  • Péter IGAZ (egyetemi tanár, Semmelweis Egyetem, Belgyógyászati és Onkológiai Klinika, Budapest)
  • Ferenc JAKAB (c. egyetemi tanár, Uzsoki Utcai Kórház, Sebészet, Budapest)
  • Zoltán JANKA (professor emeritus, Szegedi Tudományegyetem, Szent-Györgyi Albert Orvostudományi Kar és Klinikai Központ, Pszichiátriai Klinika, Szeged)
  • András JÁNOSI (c. egyetemi tanár, Gottsegen György Országos Kardiovaszkuláris Intézet, Nemzeti Szívinfartkus Regiszter, Budapest)
  • György JERMENDY (egyetemi tanár, Bajcsy-Zsilinszky Kórház, Belgyógyászat, Budapest)
  • László KALABAY (egyetemi tanár, Semmelweis Egyetem, Családorvosi Tanszék, Budapest)
  • Anita KAMONDI (egyetemi tanár, Országos Mentális, Ideggyógyászati és Idegsebészeti Intézet, Neurológiai Osztály, Budapest)
  • János KAPPELMAYER (egyetemi tanár, Debreceni Egyetem, Laboratóriumi Medicina Intézet, Debrecen)
  • Éva KELLER (ny. egyetemi tanár, Semmelweis Egyetem, Igazságügyi és Biztosítás-orvostani Intézet, Budapest)
  • Mátyás KELTAI (ny. egyetemi docens, Gottsegen György Országos Kardiovaszkuláris Intézet, Nemzeti Szívinfartkus Regiszter, Budapest)
  • András KISS (egyetemi tanár, Semmelweis Egyetem, II. Patológiai Intézet, Budapest)
  • Lajos KULLMANN (ny. egyetemi tanár, Országos Rehabilitációs Intézet, Budapest)
  • Emese MEZŐSI (egyetemi tanár, Pécsi Tudományegyetem, I. Belgyógyászati Klinika, Pécs)
  • László MÓDIS (egyetemi tanár, Debreceni Egyetem, Általános Orvostudományi Kar, Szemészeti Tanszék, Debrecen)
  • Györgyi MŰZES (egyetemi docens, Semmelweis Egyetem, Belgyógyászati és Hematológiai Klinika, Budapest)
  • Bálint NAGY (egyetemi tanár, Debreceni Egyetem, Humángenetikai Tanszék, Debrecen)
  • Endre NAGY (egyetemi tanár, Debreceni Egyetem, Belgyógyászati Intézet, Debrecen) 
  • Péter NAGY (egyetemi tanár, Semmelweis Egyetem, I. Patológiai és Kísérleti Rákkutató Intézet, Budapest)
  • Viktor NAGY (főorvos, Semmelweis Egyetem, Belgyógyászati és Hematológiai Klinika, Budapest)
  • Zoltán Zsolt NAGY (egyetemi tanár, Semmelweis Egyetem, Szemészeti Klinika, Budapest)
  • Attila PATÓCS (tudományos főmunkatárs, Semmelweis Egyetem, Belgyógyászati és Hematológiai Klinika, Budapest)
  • Gabriella PÁR (egyetemi docens, Pécsi Tudományegyetem, I. Belgyógyászati Klinika)
  • György PFLIEGLER (egyetemi tanár, Debreceni Egyetem, Ritka Betegségek Tanszéke, Debrecen)
  • István RÁCZ (egyetemi tanár, főorvos, Petz Aladár Megyei Oktató Kórház, Belgyógyászat, Győr)
  • Imre ROMICS (professor emeritus, Semmelweis Egyetem, Urológiai Klinika, Budapest)
  • László Jr. ROMICS (Angliában dolgozik) 
  • Imre RURIK (egyetemi tanár, Debreceni Egyetem, Családorvosi és Foglalkozás-egészségügyi Tanszék, Debrecen)
  • Péter SCHMIDT (házi gyermekorvos, Győr)
  • Gábor SIMONYI (vezető főorvos, Szent Imre Kórház, Anyagcsere Központ, Budapest)
  • Gábor Márk SOMFAI (egyetemi docens, Semmelweis Egyetem, Szemészeti Klinika, Budapest)
  • Anikó SOMOGYI (ny. egyetemi tanár, Semmelweis Egyetem, Belgyógyászati és Hematológiai Klinika, Budapest)
  • Péter SÓTONYI (professor emeritus, Semmelweis Egyetem, Igazságügyi és Biztosítás-orvostani Intézet, Budapest)
  • Péter Jr. SÓTONYI (egyetemi tanár, Semmelweis Egyetem, Városmajori Szív- és Érsebészeti Klinika, Budapest)
  • Ildikó SÜVEGES (professor emeritus, Semmelweis Egyetem, Szemészeti Klinika, Budapest)
  • György SZABÓ (professor emeritus, Semmelweis Egyetem, Arc-Állcsont-Szájsebészeti és Fogászati Klinika, Budapest)
  • Ferenc SZALAY (professor emeritus, Semmelweis Egyetem, Belgyógyászati és Onkológiai Klinika, Budapest)
  • György SZEIFERT (egyetemi magántanár, Semmelweis Egyetem, Általános Orvostudományi Kar, Idegsebészeti Tanszék, Budapest)
  • Miklós SZENDRŐI (professor emeritus, Semmelweis Egyetem, Ortopédiai Klinika, Budapest)
  • István SZILVÁSI (egyetemi tanár, Semmelweis Egyetem, Belgyógyászati és Hematológiai Klinika, Budapest)
  • Miklós TÓTH (egyetemi tanár, Semmelweis Egyetem, Belgyógyászati és Onkológiai Klinika, Budapest)
  • László TRINGER (professor emeritus, Semmelweis Egyetem, Pszichiátriai és Pszichoterápiás Klinika, Budapest)
  • Tivadar TULASSAY (professor emeritus, Semmelweis Egyetem, I. Gyermekgyógyászati Klinika, Budapest)
  • Zsolt TULASSAY (professor emeritus, Semmelweis Egyetem, Belgyógyászati és Hematológiai Klinika, Budapest)
  • Lívia VASAS (ny. könyvtárigazgató, Semmelweis Egyetem, Központi Könyvtár, Budapest)
  • Barna VÁSÁRHELYI (egyetemi tanár, Semmelweis Egyetem, Laboratóriumi Medicina Intézet, Budapest)
  • László VÉCSEI (professor emeritus, Szegedi Tudományegyetem, Neurológiai Klinika, Szeged)
  • Gábor WINKLER (egyetemi tanár, Szent János Kórház, Belgyógyászati Osztály, Budapest)

Nemzetközi szerkesztőbizottság - International Editorial Board:

  • Elnök/President Péter SÓTONYI (Budapest)
  • Ernest ADEGHATE (Al Ain)
  • Ferenc ANTONI (Edinburgh)
  • Maciej BANACH (Łódź)
  • Klára BERENCSI (Rosemont)
  • Angelo BIGNAMINI (Milano)
  • Anupam BISHAYEE (Signal Hill)
  • Hubert E. BLUM (Freiburg)
  • G. László BOROS (Los Angeles)
  • Frank A. CHERVENAK (New York)
  • József DÉZSY (Wien)
  • Peter ECKL (Salzburg)
  • Péter FERENCI (Wien)
  • Madelaine HAHN (Erlangen)
  • S. Tamás ILLÉS (Bruxelles)
  • Michael KIDD (Toronto)
  • Andrzej KOKOSZKA (Warsaw)
  • Márta KORBONITS (London)
  • Asim KURJAK (Zagreb)
  • Manfred MAIER (Wien)
  • Lajos OKOLICSÁNYI (Padova)
  • Amado Salvador PENA (Amsterdam)
  • Guliano RAMADORI (Goettingen)
  • Olivér RÁCZ (Košice)
  • Roberto ROMERO (Detroit)
  • Rainer SCHÖFL (Linz)
  • Zvi VERED (Tel Aviv)
  • Josef VESELY (Olomouc)
  • Ákos ZAHÁR (Hamburg)

Akadémiai Kiadó Zrt. 1117 Budapest
Budafoki út 187-189.
A épület, III. emelet
Phone: (+36 1) 464 8235
Email: orvosihetilap@akademiai.hu

  • Web of Science SCIE
  • Scopus
  • Medline
  • CABELLS Journalytics

2022  
Web of Science  
Total Cites
WoS
1295
Journal Impact Factor 0.6
Rank by Impact Factor

Medicine, General & Integral (Q4)

Impact Factor
without
Journal Self Cites
0.3
5 Year
Impact Factor
0.5
Journal Citation Indicator 0.15
Rank by Journal Citation Indicator

Medicine, General & Integral (Q3)

Scimago  
Scimago
H-index
24
Scimago
Journal Rank
0.182
Scimago Quartile Score

Medicine (miscellaneous) (Q4)

Scopus  
Scopus
Cite Score
1.0
Scopus
CIte Score Rank
General Medicine 530/830 (36th PCTL)
Scopus
SNIP
0.290

2021  
Web of Science  
Total Cites
WoS
1386
Journal Impact Factor 0,707
Rank by Impact Factor Medicine, General & Internal 158/172
Impact Factor
without
Journal Self Cites
0,407
5 Year
Impact Factor
0,572
Journal Citation Indicator 0,15
Rank by Journal Citation Indicator Medicine, General & Internal 214/329
Scimago  
Scimago
H-index
23
Scimago
Journal Rank
0,184
Scimago Quartile Score Medicine (miscellaneous) (Q4)
Scopus  
Scopus
Cite Score
0,9
Scopus
CIte Score Rank
General Medicine 528/826 (Q3)
Scopus
SNIP
0,242

2020  
Total Cites 1277
WoS
Journal
Impact Factor
0,540
Rank by Medicine, General & Internal 155/169 (Q4)
Impact Factor  
Impact Factor 0,310
without
Journal Self Cites
5 Year 0,461
Impact Factor
Journal  0,17
Citation Indicator  
Rank by Journal  Medicine, General & Internal 203/313 (Q4)
Citation Indicator   
Citable 261
Items
Total 229
Articles
Total 32
Reviews
Scimago 21
H-index
Scimago 0,176
Journal Rank
Scimago Medicine (miscellaneous) Q4
Quartile Score  
Scopus 921/1187=0,8
Scite Score  
Scopus General Medicine 494/793 (Q3)
Scite Score Rank  
Scopus 0,283
SNIP  
Days from  28
submission  
to acceptance  
Days from  114
acceptance  
to publication  
Acceptance 72%
Rate

2019  
Total Cites
WoS
1 085
Impact Factor 0,497
Impact Factor
without
Journal Self Cites
0,212
5 Year
Impact Factor
0,396
Immediacy
Index
0,126
Citable
Items
247
Total
Articles
176
Total
Reviews
71
Cited
Half-Life
6,1
Citing
Half-Life
7,3
Eigenfactor
Score
0,00071
Article Influence
Score
0,045
% Articles
in
Citable Items
71,26
Normalized
Eigenfactor
0,08759
Average
IF
Percentile
10,606
Scimago
H-index
20
Scimago
Journal Rank
0,176
Scopus
Scite Score
864/1178=0,4
Scopus
Scite Score Rank
General Medicine 267/529 (Q3)
Scopus
SNIP
0,254
Acceptance
Rate
73%

 

Orvosi Hetilap
Publication Model Hybrid
Submission Fee none
Article Processing Charge 900 EUR/article
Printed Color Illustrations 20 EUR (or 5000 HUF) + VAT / piece
Regional discounts on country of the funding agency World Bank Lower-middle-income economies: 50%
World Bank Low-income economies: 100%
Further Discounts Editorial Board / Advisory Board members: 50%
Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100%
Subscription fee 2023 Online subsscription: 858 EUR / 1157 USD
Print + online subscription: 975 EUR / 1352 USD
Subscription Information Online subscribers are entitled access to all back issues published by Akadémiai Kiadó for each title for the duration of the subscription, as well as Online First content for the subscribed content.
Purchase per Title Individual articles are sold on the displayed price.

Orvosi Hetilap
Language Hungarian
Size A4
Year of
Foundation
1857
Volumes
per Year
1
Issues
per Year
52
Founder Markusovszky Lajos Alapítvány -- Lajos Markusovszky Foundation
Founder's
Address
H-1088 Budapest, Szentkriályi u. 46.
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 0030-6002 (Print)
ISSN 1788-6120 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Nov 2023 0 24 77
Dec 2023 0 156 61
Jan 2024 0 92 15
Feb 2024 0 73 14
Mar 2024 0 40 17
Apr 2024 0 48 21
May 2024 0 0 0